<DOC>
	<DOC>NCT03054350</DOC>
	<brief_summary>This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, PK, and PD of orally administered vadadustat in Japanese subjects with anemia secondary to DD-CKD.</brief_summary>
	<brief_title>Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Male and female Japanese subjects â‰¥20 years of age Receiving chronic maintenance hemodialysis for endstage kidney disease Hb &lt;10.0 g/dL Anemia due to a cause other than CKD or presence of active bleeding or recent blood loss Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia Red blood cell transfusion within 4 weeks prior to or during screening Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anemia</keyword>
	<keyword>kidney</keyword>
	<keyword>dialysis-dependent chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>DD-CKD</keyword>
	<keyword>renal</keyword>
	<keyword>vadadustat</keyword>
	<keyword>AKB-6548</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>hypoxia-inducible factor prolyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
	<keyword>Japan</keyword>
	<keyword>Japanese</keyword>
</DOC>